Has Mario Rangel received payments from drug or device companies?

Yes. Drug and device makers reported $3,633 in general payments to Mario Rangel across 137 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mario Rangel did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mario Rangel come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mario Rangel

General Practice · Alamo, TXNPI 1306967708

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Among general practice clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,633in general payments, 2019–2025

Across 137 payments — averaging $26.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$721
AstraZeneca$683
Lilly USA, LLC$505
Amgen$280
Bayer$263
GSK$239
plus $942 from 18 others

What the payments were for

Food & beverage$3,633100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	22	$721
AstraZeneca	20	$683
Lilly USA, LLC	27	$505
Amgen	6	$280
Bayer	14	$263
GSK	7	$239
Otsuka America Pharmaceutical, Inc.	8	$185
Redhill Biopharma Inc.	5	$139
Abbott	1	$100
Axsome Therapeutics, Inc.	3	$80
Boehringer Ingelheim	2	$45
Sanofi-aventis U.S. LLC	3	$44
Exact Sciences	2	$42
Corium, LLC	2	$37
Pfizer	2	$35
Astellas Pharma US Inc	2	$34
Sumitomo Pharma America, Inc.	2	$32
AbbVie	2	$31
Corcept Therapeutics	1	$28
Amarin Pharma, Inc.	2	$26
Ardelyx, Inc.	1	$26
Kowa Pharmaceuticals America, Inc.	1	$21
Johnson & Johnson	1	$20
Mannkind Corporation	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,633 in reported general payments places this provider in the 95th percentile of 8,074 general practice providers in Texas.

See all general practice providers in Texas →

Other general practice in Alamo

Marcus LastimadoFort Bliss$2.3M
Christina DeanFrisco$1.9M
Paul ShrodeMissouri City$1.2M
Alan DouglasSan Antonio$609K
C Mike MeekAustin$509K
Young KwonDallas$288K
Matthew HicksFriendswood$268K
Kathleen Szelei-StevensHouston$253K
Hoa TranPearland$156K
Mitchell KimRichardson$145K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →